Selected 7b-(benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins (1a–e) were synthesised and tested for their antimicrobial activity against Gram-positive and Gram-negative clinical pathogens. All compounds synthesised (1a–e) showed an in vitro antimicrobial activity similar to that of ceftriaxone and cefpirome against the Gram-positive bacteria, and superior to that of penicillin and cefaclor against pen-R Staphylococcus aureus species. Like all b-lactam agents, compounds 1a–e were in an inactive Minimum Inhibitory Concentration (MIC > 32 μg/ml) against methicillin-resistant S. aureus species. Furthermore, as expected, no cross-resistance was observed against the erythromycin-resistant Staphylococcus pyogenes strain. Finally, it is worth underlining that compounds 1a and 1e showed a similar activity to that of ceftriaxone and superior to cefaclor against penicillin-resistant Streptococcus pneumoniae isolates, a key respiratory tract infection (RTI) causing pathogen difficult to treat with currently marketed antibiotics.
SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF NEW 7BETA-(BENZO[A]DIHYDROCARBAZOLYLOXYACETYL)-SUBSTITUTED CEPHALOSPORINS
ROSSELLO, ARMANDO;ORLANDINI, ELISABETTA;NUTI, ELISA;RAPPOSELLI, SIMONA;MACCHIA, MARCO;
2004-01-01
Abstract
Selected 7b-(benzo[a]dihydrocarbazolyloxyacetyl)-substituted cephalosporins (1a–e) were synthesised and tested for their antimicrobial activity against Gram-positive and Gram-negative clinical pathogens. All compounds synthesised (1a–e) showed an in vitro antimicrobial activity similar to that of ceftriaxone and cefpirome against the Gram-positive bacteria, and superior to that of penicillin and cefaclor against pen-R Staphylococcus aureus species. Like all b-lactam agents, compounds 1a–e were in an inactive Minimum Inhibitory Concentration (MIC > 32 μg/ml) against methicillin-resistant S. aureus species. Furthermore, as expected, no cross-resistance was observed against the erythromycin-resistant Staphylococcus pyogenes strain. Finally, it is worth underlining that compounds 1a and 1e showed a similar activity to that of ceftriaxone and superior to cefaclor against penicillin-resistant Streptococcus pneumoniae isolates, a key respiratory tract infection (RTI) causing pathogen difficult to treat with currently marketed antibiotics.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
